Artigos de revistas sobre o tema "Psychotropic drugs – pharmacokinetics"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Psychotropic drugs – pharmacokinetics".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Fernandes Santos, C., e R. Gomes. "Specificities of the Use of Psychotropic Drugs in Bariatric Surgery". European Psychiatry 65, S1 (junho de 2022): S478—S479. http://dx.doi.org/10.1192/j.eurpsy.2022.1216.
Texto completo da fonteBOURIN, M., e A. COUETOUX DU TERTRE. "PHARMACOKINETICS OF PSYCHOTROPIC DRUGS IN CHILDREN." Clinical Neuropharmacology 15 (1992): 224A—225A. http://dx.doi.org/10.1097/00002826-199201001-00117.
Texto completo da fonteSit, D. K., J. M. Perel, J. Helsel e K. L. Wisner. "Pharmacokinetics of psychotropic drugs in pregnancy". Neurotoxicology and Teratology 29, n.º 3 (maio de 2007): 411. http://dx.doi.org/10.1016/j.ntt.2007.03.051.
Texto completo da fonteBurns, Alistair, e Robert Baldwin. "Prescribing psychotropic drugs for the elderly". Advances in Psychiatric Treatment 1, n.º 1 (setembro de 1994): 23–31. http://dx.doi.org/10.1192/apt.1.1.23.
Texto completo da fonteMarazziti, Donatella, Stefano Baroni, Michela Picchetti, Armando Piccinni, Marina Carlini, Elena Vatteroni, Valentina Falaschi, Amedeo Lombardi e Liliana Dell'Osso. "Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex". CNS Spectrums 18, n.º 3 (4 de fevereiro de 2013): 118–27. http://dx.doi.org/10.1017/s1092852912001010.
Texto completo da fonteBaumann, P. "JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatments’ improvements". European Psychiatry 26, S2 (março de 2011): 1995. http://dx.doi.org/10.1016/s0924-9338(11)73698-7.
Texto completo da fontePichini, Simona, Esther Papaseit, Xavier Joya, Oriol Vall, Magí Farré, Oscar Garcia-Algar e Rafael de laTorre. "Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics". Therapeutic Drug Monitoring 31, n.º 3 (junho de 2009): 283–318. http://dx.doi.org/10.1097/ftd.0b013e31819f3328.
Texto completo da fonteIannaccone, Teresa, Carmine Sellitto, Valentina Manzo, Francesca Colucci, Valentina Giudice, Berenice Stefanelli, Antonio Iuliano, Giulio Corrivetti e Amelia Filippelli. "Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters". Pharmaceuticals 14, n.º 3 (1 de março de 2021): 204. http://dx.doi.org/10.3390/ph14030204.
Texto completo da fonteMoschny, Nicole, Gudrun Hefner, Renate Grohmann, Gabriel Eckermann, Hannah B. Maier, Johanna Seifert, Johannes Heck et al. "Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics". Pharmaceuticals 14, n.º 6 (27 de maio de 2021): 514. http://dx.doi.org/10.3390/ph14060514.
Texto completo da fonteTelles-Correia, Diogo, António Barbosa, Helena Cortez-Pinto, Carlos Campos, Nuno B. F. Rocha e Sérgio Machado. "Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity". World Journal of Gastrointestinal Pharmacology and Therapeutics 8, n.º 1 (2017): 26. http://dx.doi.org/10.4292/wjgpt.v8.i1.26.
Texto completo da fonteAthanasiu, Lavinia, Lisa-Lena H. Smorr, Martin Tesli, Jan I. Røssberg, Ida E. Sønderby, Olav Spigset, Srdjan Djurovic e Ole A. Andreassen. "Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs". Journal of Psychopharmacology 29, n.º 8 (5 de maio de 2015): 884–91. http://dx.doi.org/10.1177/0269881115584469.
Texto completo da fonteDeVane, C. Lindsay, e David W. Boulton. "Great Expectations in Stereochemistry: Focus on Antidepressants". CNS Spectrums 7, S1 (abril de 2002): 28–33. http://dx.doi.org/10.1017/s1092852900028571.
Texto completo da fonteJorge, B., C. Pedro, J. Carvalho, S. Carneiro e M. Mangas. "428 - Reflections on geriatric psychopharmacology in Portugal". International Psychogeriatrics 33, S1 (outubro de 2021): 48–49. http://dx.doi.org/10.1017/s1041610221001873.
Texto completo da fonteDarnaud, Léa, Clément Delage, Youssef Daali, Anne-Priscille Trouvin, Serge Perrot, Nihel Khoudour, Nadia Merise et al. "Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs". Pharmaceutics 15, n.º 3 (18 de março de 2023): 979. http://dx.doi.org/10.3390/pharmaceutics15030979.
Texto completo da fonteYoshida, K., B. Smith e R. Kumar. "Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding". Journal of Psychopharmacology 13, n.º 1 (janeiro de 1999): 64–80. http://dx.doi.org/10.1177/026988119901300108.
Texto completo da fonteLin, Shih-Ku. "Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians". Journal of Personalized Medicine 12, n.º 9 (24 de agosto de 2022): 1362. http://dx.doi.org/10.3390/jpm12091362.
Texto completo da fonteSchjøtt, Jan, Lillan Mo Andreassen, Gro Helen Dale e Charlotte Lorentze Stokes. "Review of Clinical Questions Submitted to Norwegian Drug Information Centres Concerning Administration and Dosage to Older Patients of Relevance to Patient-Centric Care". Pharmaceutics 13, n.º 1 (14 de janeiro de 2021): 105. http://dx.doi.org/10.3390/pharmaceutics13010105.
Texto completo da fonteLeonova, M. V. "Drug-induced arrhythmias". Meditsinskiy sovet = Medical Council, n.º 21 (17 de janeiro de 2021): 26–40. http://dx.doi.org/10.21518/2079-701x-2020-21-26-40.
Texto completo da fonteTherrien, Rachel. "Managing Psychotropic Drugs with Efavirenz". Canadian Journal of Infectious Diseases and Medical Microbiology 17, suppl d (2006): 15D—16D. http://dx.doi.org/10.1155/2006/736415.
Texto completo da fonteGoodlet, Kellie J., Monika T. Zmarlicka e Alyssa M. Peckham. "Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs". CNS Spectrums 24, n.º 03 (8 de outubro de 2018): 287–312. http://dx.doi.org/10.1017/s109285291800113x.
Texto completo da fonteKolyvanov, G. B., A. A. Litvin, R. V. Shevchenko, S. Yu Raskin, P. O. Bochkov e V. P. Zherdev. "Pharmacokinetic relationships in psychotropic drugs effects". Pharmacokinetics and Pharmacodynamics, n.º 4 (25 de junho de 2021): 3–8. http://dx.doi.org/10.37489/2587-7836-2020-4-3-8.
Texto completo da fonteChadwick, Ben, Derek G. Waller e J. Guy Edwards. "Potentially hazardous drug interactions with psychotropics". Advances in Psychiatric Treatment 11, n.º 6 (novembro de 2005): 440–49. http://dx.doi.org/10.1192/apt.11.6.440.
Texto completo da fonteBlier, Pierre. "Generic Substitution for Psychotropic Drugs". CNS Spectrums 14, n.º 9 (setembro de 2009): 1–7. http://dx.doi.org/10.1017/s1092852900024706.
Texto completo da fontePetrykiv, S., M. Arts e L. De Jonge. "Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs". European Psychiatry 65, S1 (junho de 2022): S454. http://dx.doi.org/10.1192/j.eurpsy.2022.1152.
Texto completo da fonteBaumann, P. "Clinical effectiveness of psychotropic drugs: Pharmacokinetic and pharmacogenetic determinants". European Psychiatry 25 (2010): 167. http://dx.doi.org/10.1016/s0924-9338(10)70167-x.
Texto completo da fonteKarimov, Artur Udalisovich, Maxim Leonidovich Maximov, Dmitry Germanovich Semenikhin e Linar Arturovich Karimov. "Topical issues of interaction of psychotropic drugs". Vrač skoroj pomoŝi (Emergency Doctor), n.º 3 (1 de março de 2021): 27–38. http://dx.doi.org/10.33920/med-02-2103-02.
Texto completo da fonteMoran, Michael G., e Troy L. Thompson. "Changes in the Aging Brain as They Affect Psychotropics: A Review". International Journal of Psychiatry in Medicine 18, n.º 2 (junho de 1989): 137–44. http://dx.doi.org/10.2190/p60g-3ctc-26wt-43t8.
Texto completo da fonteHiemke, C. "The interactions between COVID-19 drugs and psychotropic agents". European Psychiatry 64, S1 (abril de 2021): S15. http://dx.doi.org/10.1192/j.eurpsy.2021.63.
Texto completo da fonteWieck, A. "Should we monitor psychotropic drug levels in pregnancy and the postpartum period to reduce risks of recurrence?" European Psychiatry 64, S1 (abril de 2021): S42—S43. http://dx.doi.org/10.1192/j.eurpsy.2021.142.
Texto completo da fonteSchlatter, Chantal, Sabin S. Egger, Lydia Tchambaz e Stephan Krähenbühl. "Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease". Drug Safety 32, n.º 7 (julho de 2009): 561–78. http://dx.doi.org/10.2165/00002018-200932070-00003.
Texto completo da fonteSpina, Edoardo, e Emilio Perucca. "Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs". Epilepsia 43 (19 de março de 2002): 37–44. http://dx.doi.org/10.1046/j.1528-1157.2002.043s2037.x.
Texto completo da fonteYasui-Furukori, Norio, Tomonori Tateishi, Tsuyoshi Kondo, Kazuo Mihara, Akihito Suzuki, Shingo Ono e Sunao Kaneko. "Effect of CYP2D6 genotype on pharmacokinetic interactions with psychotropic drugs". International Congress Series 1244 (julho de 2002): 21–31. http://dx.doi.org/10.1016/s0531-5131(02)00453-3.
Texto completo da fontePisani, F., E. Perucca e R. Di Perri. "Clinically Relevant Anti-Epileptic Drug Interactions". Journal of International Medical Research 18, n.º 1 (janeiro de 1990): 1–15. http://dx.doi.org/10.1177/030006059001800102.
Texto completo da fonteBishara, Delia, Chris Kalafatis e David Taylor. "Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents". Therapeutic Advances in Psychopharmacology 10 (janeiro de 2020): 204512532093530. http://dx.doi.org/10.1177/2045125320935306.
Texto completo da fonteSpina, Edoardo, e Achille P. Caputi. "Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications". Pharmacological Research 29, n.º 2 (fevereiro de 1994): 121–37. http://dx.doi.org/10.1016/1043-6618(94)80036-7.
Texto completo da fonteBayanov, A. "A pharmacokinetic study of paradoxical reactions to psychotropic drugs in children with ADHD". European Neuropsychopharmacology 12 (outubro de 2002): 404–5. http://dx.doi.org/10.1016/s0924-977x(02)80690-3.
Texto completo da fonteGrady, Meghan M., e Stephen M. Stahl. "A Horse of a Different Color: How Formulation Influences Medication Effects". CNS Spectrums 17, n.º 2 (9 de maio de 2012): 63–69. http://dx.doi.org/10.1017/s1092852912000442.
Texto completo da fonteSantos, Jaqueline Rocha Borges dos, Larrysa de Morais Alves da Cruz, Luís Phillipe Nagem Lopes e Maria Eline Matheus. "Tobacco consumption during the COVID-19 pandemic and pharmacokinetic interaction involving cytochrome P-450 with psychoactive drugs: an integrative review". Research, Society and Development 11, n.º 10 (28 de julho de 2022): e222111032349. http://dx.doi.org/10.33448/rsd-v11i10.32349.
Texto completo da fontePrisco, V., T. Iannaccone, A. Capuano, M. Fabrazzo e F. Catapano. "Drug safety warnings in psychiatry: Adverse drug reactions’ signaling from 2002 to 2014". European Psychiatry 41, S1 (abril de 2017): S758. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1420.
Texto completo da fonteWoroń, Jarosław. "Pharmacotherapy of breakthrough pain, what else can we do to improve the effectiveness of treatment". BÓL 20, n.º 4 (7 de abril de 2020): 1–11. http://dx.doi.org/10.5604/01.3001.0014.0914.
Texto completo da fonteChen, LiZhu, DeQiu Zhu e Ping Xiang. "Recent advances in chiral analysis for biosamples in clinical research and forensic toxicology". Bioanalysis 13, n.º 6 (março de 2021): 493–511. http://dx.doi.org/10.4155/bio-2020-0330.
Texto completo da fonteCurto, Martina, Luana Lionetto, Maria Chiara David, Aniello Maiese, Stefano Ferracuti, Maurizio Simmaco e Ross J. Baldessarini. "Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings". Current Psychopharmacology 8, n.º 3 (13 de dezembro de 2019): 238–43. http://dx.doi.org/10.2174/2211556008666190916093915.
Texto completo da fonteBoyce, Richard D., Carol Collins, Marc Clayton, John Kloke e John R. Horn. "Inhibitory Metabolic Drug Interactions with Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence in Drug Interaction Screening Software". Annals of Pharmacotherapy 46, n.º 10 (outubro de 2012): 1287–98. http://dx.doi.org/10.1345/aph.1r150.
Texto completo da fonteBaumann, Pierre, e Gilles Bertschy. "Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs". Nordic Journal of Psychiatry 47, sup30 (janeiro de 1993): 13–19. http://dx.doi.org/10.3109/08039489309104120.
Texto completo da fonteFagiolini, A. "Advanced Psychopharmacology: Practical Strategies for Rational Polypharmacy in Mood Disorders". European Psychiatry 24, S1 (janeiro de 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70254-8.
Texto completo da fonteSabaté, M. Betriu, A. González-Rodríguez, A. Guàrdia, E. Pérez-Macho, A. Alvarez Pedrero, S. Acebillo, J. A. Monreal, D. Palao Vidal e J. Labad. "Pharmacokinetic interactions of psychotropic medications in patients with schizophrenia suffering from atypical mycobacterial infections". European Psychiatry 64, S1 (abril de 2021): S649—S650. http://dx.doi.org/10.1192/j.eurpsy.2021.1725.
Texto completo da fonteKadasah, Sultan F., Abdulaziz M. S. Alqahtani, Abdullah Alkhammash e Mohamed O. Radwan. "Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy". International Journal of Molecular Sciences 25, n.º 12 (7 de junho de 2024): 6314. http://dx.doi.org/10.3390/ijms25126314.
Texto completo da fonteBaumann, P., e W. Greil. "Clinical pharmacological management of polypharmacy in old age depression". European Psychiatry 33, S1 (março de 2016): S39. http://dx.doi.org/10.1016/j.eurpsy.2016.01.881.
Texto completo da fonteEnglisch, Susanne, Hanna Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Sarah Eisenacher, Jascha Thiem, Andreas Meyer-Lindenberg e Mathias Zink. "Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study". Pharmacopsychiatry 52, n.º 03 (7 de maio de 2018): 142–46. http://dx.doi.org/10.1055/a-0606-5240.
Texto completo da fonteGillman, Peter Kenneth, Vincent Van den Eynde, Lila Godet, Charles Redhead, Alexander Horwitz e Brian Barnett. "Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions". Psychiatric Annals 53, n.º 8 (agosto de 2023): 353–58. http://dx.doi.org/10.3928/00485713-20230713-02.
Texto completo da fonte